Targeted therapy combination improves survival in patients with advanced bowel cancer
IMAGE: LBA-006 ‘BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic… view more Credit: European Society for Medical Oncology Barcelona, Spain, 6 July 2019 – New data have shown for the first time that a combination…